Agriculture
your username
February 16, 2021
The United States filed a complaint on Friday against Patriot Marine, LLC asking for the Massachusetts District Court to require the company to pay removal costs the plaintiff has already paid to clean up oil released into the waters of Great Harbor, Woods Hole, Massachusetts in January 2018.
According to the complaint, oil spill cleanups can be financed through an Oil Spill Liability Trust Fund, which was used to clean up this specific spill, but the plaintiff purported that the defendants should still be liable for the costs under the Oil Pollution Act of 1990. The costs the United States is seeking payment for included “all removal costs, natural resource damages, and interest resulting from the oil spill.” The complaint specified that the United States is not seeking natural resource damages or a judgment relating to the amount of destruction occurring through the oil spill to the environment or natural resources.
More than 4,700 OUI defendants in Worcester County may be eligible for a new trial because of breath test evidence issues
Updated Feb 10, 2021;
Worcester County defendants charged with operating under the influence of alcohol based on breath tests conducted over the last decade may be entitled to new trials, Worcester District Attorney Joseph D. Early Jr. said on Wednesday.
More than 4,700 Worcester County defendants will receive letters in the mail alerting them about the possibility of having their cases re-examined because of “problems with Breathalyzer evidence,” Early said.
Breath tests between 2011 and 2018 used in criminal trials were declared to be inadmissible evidence in a Northwestern district attorney decision announced on Monday. The letters from the trial court were sent to OUI defendants in Worcester County this week, officials said.
Thousands with OUI convictions to be offered new trials over unreliable breath tests
Published: 2/8/2021 8:18:04 PM
NORTHAMPTON Thousands of people in Hampshire and Franklin counties who were convicted of drunken driving between 2011 and 2018 may soon be eligible for a second trial due to unreliable breath test results, the office of the Northwestern district attorney announced Monday.
The office will send out letters to 3,100 residents of the two counties this week notifying them of their right to challenge a conviction for operating under the influence (OUI) from this period. Statewide, an estimated 27,000 people will receive notices.
Massachusetts District Court Judge Robert Brennan determined in 2017 that blood alcohol content test devices enacted by the state’s Office of Alcohol Testing from 2011-14 did not produce scientifically reliable results, making these tests inadmissible in court. In 2019, Brennan determined that the Office of Alcohol Testing had intentionally
Thousands with OUI convictions to be offered new trials over unreliable breath tests
Modified: 2/9/2021 3:11:12 PM
NORTHAMPTON Thousands of people in Hampshire and Franklin counties who were convicted of drunken driving between 2011 and 2018 may soon be eligible for a second trial due to unreliable breath test results, the office of the Northwestern district attorney announced Monday.
The office will send out letters to 3,100 residents of the two counties this week notifying them of their right to challenge a conviction for operating under the influence (OUI) from this period. Statewide, an estimated 27,000 people will receive notices.
Massachusetts District Court Judge Robert Brennan determined in 2017 that blood alcohol content test devices enacted by the state’s Office of Alcohol Testing from 2011-14 did not produce scientifically reliable results, making these tests inadmissible in court. In 2019, Brennan determined that the Office of Alcohol Testing had intentionally w
Health
your username
January 12, 2021
Minerva Neuroscience is facing a putative class-action securities lawsuit filed by an investor in Massachusetts District Court. According to the complaint, the NASDAQ-listed company is a “clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous diseases.” The complaint alleges that misleading statements made by the company and its CEO concerning the outcomes of Food and Drug Administration (FDA) trials resulted in a decrease in stock price.
At the center of the suit is roluperidone, or MIN-101, a drug being developed for the treatment of symptoms of schizophrenia. The complaint explained that the Class Period began in May 2017, when the defendant announced that it had held a successful Phase 2b trial with the FDA, and would undertake a Phase 3 trial.